Table 4.
Adjusted Odds Ratios for the Association Between EOC Risk and Body Powder by Menopausal Status and Hormone Therapy Use.
| Pre-menopause | Post-menopause | |||||||
|---|---|---|---|---|---|---|---|---|
| Exposure | Cases (n=158) n (%) | Controls (n=221) n (%) | ORa | 95% CI | Cases (n=423) n (%) | Controls (n=522) n (%) | ORa | 95% CI |
| Body Powder Useb | ||||||||
| Never use | 59 (37.3) | 103 (46.6) | 1.00 | Referent | 157 (37.1) | 247 (47.3) | 1.00 | Referent |
| Only non-genital use | 22 (13.9) | 42 (19.0) | 0.90 | 0.44, 1.84 | 97 (22.9) | 98 (18.8) | 1.49 | 1.04, 2.15 |
| Any genital use | 77 (48.7) | 76 (48.7) | 1.50 | 0.87, 2.57 | 169 (40.0) | 177 (33.9) | 1.41 | 1.03, 1.92 |
| HT Ever/Never Usec,d,e | ||||||||
| HT Ever Use | ||||||||
| Never use | 34 (32.1) | 55 (48.7) | 1.00 | Referent | ||||
| Only non-genital use | 23 (21.7) | 23 (20.4) | 1.74 | 0.77, 3.92 | ||||
| Any genital use | 49 (46.2) | 35 (31.0) | 2.68 | 1.33, 5.40 | ||||
| HT Never Use | ||||||||
| Never use | 122 (38.9) | 191 (46.9) | 1.00 | Referent | ||||
| Only non-genital use | 73 (23.3) | 75 (18.4) | 1.51 | 0.99, 2.29 | ||||
| Any genital use | 119 (37.9) | 141 (34.6) | 1.24 | 0.87, 1.79 | ||||
Abbreviations: epithelial ovarian cancer (EOC); hormone therapy (HT).
Adjusted for age at diagnosis/interview, study site, education, tubal ligation, parity, BMI, duration of OC use, first degree family history of breast or ovarian cancer, and interview year.
Test for interaction between menopausal status and route of body powder exposure was non-significant for only non-genital use (p=0.21) and any genital use (p=0.85) compared with never use.
Restricted to post-menopausal women.
Test for interaction between HT use and only non-genital use was non-significant (p=0.76).
Test for interaction between HT use and any genital use was non-significant (p=0.06).